{"id":2768,"date":"2017-08-25T11:45:00","date_gmt":"2017-08-25T11:45:00","guid":{"rendered":"http:\/\/www.irlab.se\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/"},"modified":"2017-08-25T11:45:00","modified_gmt":"2017-08-25T11:45:00","slug":"irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752","status":"publish","type":"post","link":"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/","title":{"rendered":"IRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752"},"content":{"rendered":"

”Tillståndet från Läkemedelsverket och Etikprövningsnämnden innebär att vi kan genomföra denna dubbelblinda placebokontrollerade Fas II-studie med IRL752 för behandling av patienter med Parkinsons sjukdom och demens. Upp emot 80 procent av alla som drabbas av Parkinsons sjukdom utvecklar med tiden demens, vilket ger symptom och svårigheter som idag saknar tillfredsställande behandlingsmöjligheter.” Säger Joakim Tedroff, IRLAB:s medicinska chef, CMO<\/p>\n

Fas II-studien kommer att studera hur kognitiva och motoriska funktioner påverkas av behandling med IRL752 hos patienter med Parkinsons sjukdom och demens. I studien kommer även information från patienternas anhöriga och vårdare inhämtas för att få en bredare bild av hur läkemedlet kan påverka patienternas funktion i vardagslivet. Studiens primära syfte är att undersöka säkerhet och tolererbarhet av IRL752 i denna patientgrupp.<\/p>\n

I den tidigare genomförda Fas I-studien visar resultaten att IRL752 är vältolererad och har mycket god säkerhetsprofil. Substansen gav inga oönskade effekter på vitala funktioner eller utslag i de laboratorieanalyser som ingått i studien. IRL752 uppvisar doslinjär farmakokinetik. Födointag påverkar inte upptag och distribution av substansen i kroppen.<\/p>\n

IRLAB utvecklar IRL752 för behandling av demens vid Parkinsons sjukdom. I prekliniska djurstudier har tidigare visats att IRL752 höjer halterna av signalämnen såsom dopamin, noradrenalin och acetylkolin i främre hjärnbarkens nervkopplingar. IRL752 har också uppvisat minnesförstärkande, antidepressiva och antipsykotiska effekter. Substansens goda säkerhet och tolererbarhet hos friska försökspersoner är förenligt med resultat från de prekliniska studier som tidigare genomförts med IRL752.<\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

IRLAB Therapeutics AB har erh\u00e5llit L\u00e4kemedelsverkets tillst\u00e5nd att genomf\u00f6ra en Fas II-studie med l\u00e4kemedelskandidaten IRL752. \u00c4ven Etikpr\u00f6vningsn\u00e4mnden i Stockholm har l\u00e4mnat sitt tillst\u00e5nd f\u00f6r studien.\u00a0<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23],"tags":[],"class_list":["post-2768","post","type-post","status-publish","format-standard","hentry","category-pressmeddelande-2"],"acf":[],"yoast_head":"\nIRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB Therapeutics AB har erh\u00e5llit L\u00e4kemedelsverkets tillst\u00e5nd att genomf\u00f6ra en Fas II-studie med l\u00e4kemedelskandidaten IRL752. \u00c4ven Etikpr\u00f6vningsn\u00e4mnden i Stockholm har l\u00e4mnat sitt tillst\u00e5nd f\u00f6r studien.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-25T11:45:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"IRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752\",\"datePublished\":\"2017-08-25T11:45:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/\"},\"wordCount\":340,\"commentCount\":0,\"articleSection\":[\"Pressmeddelande\"],\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/\",\"url\":\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/\",\"name\":\"IRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2017-08-25T11:45:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752 - IRLAB","og_description":"IRLAB Therapeutics AB har erh\u00e5llit L\u00e4kemedelsverkets tillst\u00e5nd att genomf\u00f6ra en Fas II-studie med l\u00e4kemedelskandidaten IRL752. \u00c4ven Etikpr\u00f6vningsn\u00e4mnden i Stockholm har l\u00e4mnat sitt tillst\u00e5nd f\u00f6r studien.\u00a0","og_url":"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/","og_site_name":"IRLAB","article_published_time":"2017-08-25T11:45:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/#article","isPartOf":{"@id":"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/"},"author":{"name":"","@id":""},"headline":"IRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752","datePublished":"2017-08-25T11:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/"},"wordCount":340,"commentCount":0,"articleSection":["Pressmeddelande"],"inLanguage":"sv-SE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/","url":"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/","name":"IRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2017-08-25T11:45:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/irlab-erhaller-tillstand-att-genomfora-fas-ii-studie-med-irl752\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"IRLAB erh\u00e5ller tillst\u00e5nd att genomf\u00f6ra Fas II-studie med IRL752"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts\/2768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/comments?post=2768"}],"version-history":[{"count":0,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts\/2768\/revisions"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=2768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/categories?post=2768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/tags?post=2768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}